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Abstract 
Background: Cycloartane triterpenoids exhibited anticancer effects. This study aims to identify any potential novel 
anticancer cycloartane triterpenoids from Cimicifuga foetida L. rhizome (Sheng ma) and the mode of actions.
Methods: Cycloartane triterpenoids were isolated from the C. foetida rhizome by a series of column chromatography 
and identified by IR, MS and NMR. Their anticancer effects on several human cancer cell lines, MCF‑7, HepG2, HepG2/
ADM, HeLa, and PC3, and normal human mammary epithelial cells MCF10A were investigated by colony formation 
and MTT assays. Morphological analysis of apoptosis induction was performed by acridine orange/ethidium bromide 
dual‑staining and Hoechst 33258 nuclear staining. The cell‑cycle profile and annexin V staining were evaluated by 
flow cytometry. Apoptosis were investigated by measuring changes in mitochondrial membrane potential and ana‑
lyzing expression of cell cycle‑ and apoptosis‑related proteins in MCF‑7 cells by Western blotting.
Results: A novel cycloartane triterpenoid, 25‑O‑acetyl‑7,8‑didehydrocimigenol‑3‑O‑β‑d‑(2‑acetyl)xylopyranoside 
(ADHC‑AXpn), together with the known 7,8‑didehydrocimigenol‑3‑O‑β‑d‑xylopyranoside (DHC‑Xpn) were isolated. 
MCF‑7 growth was significantly inhibited by ADHC‑AXpn in a dose‑ and time‑dependent manner (IC50: 27.81 µM at 
48 h; P = 0.004 vs. control at 25 μM for 48 h treatment), and ADHC‑AXpn was selectively cytotoxic for cancerous cells 
(MCF‑7, HepG2/ADM, HepG2 and HELA cells) based on its higher IC50 values for normal cells MCF10A (IC50: 78.63 µM 
at 48 h) than for tumor cells. In MCF‑7 cells, ADHC‑AXpn induced G2/M cell cycle arrest by mediating cyclin‑B1, and 
CDK1 and its phosphorylation; and induced apoptosis through the mitochondrial‑mediated apoptotic pathway, with 
inhibition of Akt activation. As ADHC‑AXpn suppressed phosphorylation of ERK1/2, Raf and Akt proteins in MCF‑7 
cells, its apoptotic effect might be associated with Raf/MEK/ERK signaling and Akt activation.
Conclusions: ADHC‑AXpn significantly suppressed the growth of MCF‑7 cells, induced mitochondrial apoptosis and 
cell‑cycle arrest, and inhibited Raf/MEK/ERK signaling pathway and Akt phosphorylation.
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Background
Chinese medicine (CM) is a rich source for the develop-
ment of anticancer drugs and chemopreventive agents 
[1]. Cycloartane triterpenoid (CATP) are triterpene gly-
cosides with a unique structural C-19 angular methyl 
(Fig. 1), are distributed in plants of several genuses, such 
as Astragalus, Cimicifuga, and Thalictrum [2, 3]. Several 
CATPs isolated from plants exhibited potential antican-
cer activities [4–7].
The rhizome of Cimicifuga foetida L. (Sheng ma), has 
been used as an anti-inflammatory, analgesic, and antipy-
retic agent in CM [8]. C. foetida contains many CATPs 
[9, 10], and some CATPs from the Cimicifuga genus 
possessed anti-cancer effects in vivo and in vitro [4–6]. 
However, previous research focused on isolation and 
structure identification rather than biological activity. 
Our earlier research associated CATP anticancer activ-
ity with apoptosis induction and cell cycle arrest in tumor 
cells [4, 5], but respective biological pathways have not 
yet investigated.
This study aims to identify any potential novel antican-
cer CATP from C. foetida and evaluate their effects on 
the growth, colony formation, apoptosis induction and 
respective pathways in cancer cells.
Methods
Plant materials
Rhizome of C. foetida was collected in Emei Mountain, 
Sichuan province, China in October 2012 and identi-
fied by Dr. Sibao Chen by comparing its morphological 
features [8]. A voucher specimen (SZRI20121045) was 
deposited in the herbarium of state key laboratory of 
Chinese medicine and molecular pharmacology.
Equipment
Infrared spectra (IR) were recorded on a Shimadzu 
IR-450 spectrometer (Shimadzu, Kyoto, Japan). High 
resolution fast atom bombardment mass spectra (HR-
FAB-MS) were recorded on a VG-Autospec-3000 
spectrometer (Micromass, Manchester, UK), in m/z 
(percentage relative intensity of base peak). The nuclear 
magnetic resonance (NMR) spectra were measured in 
pyridine-d5 on a Bruker AM-400 spectrometer (Bruk-
erDaltonics, MA, USA), using tetramethyl silane as inter-
nal standard. Silica gel-60H (100–200 and 200–300 mesh) 
and silica gel GF254 sheets (0.20–0.25  mm; both from 
Qingdao Haiyang Chemical Group Co., Qingdao, China) 
were used for column chromatography (CCG) and thin 
layer chromatography (TLC), respectively.
Materials and reagents for pharmacological investigations
3-(4, 5)-Dimethylthiazol-2-yl)-2, 5-diphenyl tetrazo-
lium bromide (MTT), Hoechst 33258, propidium iodide 
(PI), doxorubicin (Dox) and carbonyl cyanide 3-c hloro-
phenylhydrazone were purchased from Sigma-Aldrich 
(St. Louis, MO, USA). 5, 5′, 6, 6′-tetrachloro-1, 1′, 3, 
3′-tetraethyl benzimidazolyl-carbocyanine iodide (JC-
1) and Alexa Fluor® 488 Annexin V/dead cell apoptosis 
kit were obtained from invitrogen (Carlsbad, CA, USA). 
BCA protein assay kit and electro chemiluminescence 
were obtained from Thermo Fisher Scientific (Rock-
ford, IL, USA). Antibodies against cyclin B1, CDK1, 
p-CDK1(Thr161), caspase-9, cleaved caspase-9, PARP, 
cleaved PARP, Akt, p-Akt (Thr308 and Ser473), p-ERK1/2 
and p-c-Raf were from cell signaling technology (Bev-
erly, MA, USA). Antibodies against Bcl-2 and Bax were 
bought from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA). Protease inhibitor cocktail tablets and phosphatase 
inhibitor cocktail tablets were supplied by Roche (Roche 
Applied Science, Mannheim, Germany). Dimethylsulfox-
ide (DMSO); RPMI-1640 and Dulbecco’s modification 
of Eagle’s medium (DMEM), phosphate-buffered saline 
(PBS), fetal bovine serum (FBS), penicillin-streptomy-
cin (P/S) and trypsin-ethylene diamine tetraacetic acid 
(EDTA) were purchased from life technologies (Grand 
Island, NY, USA).
Extraction and isolation
The rhizome of C. foetida (0.5  kg) was extracted three 
times with 95 % EtOH for 1 h under reflux. After com-
bination of extractions and solvent removal, the residue 
(129  g) was suspended in water (1  L) and partitioned 
successively with 200  mL each of petroleum ether (60–
80  ℃), ethyl acetate and n-BuOH. The ethyl acetate 
fraction (28  g) was subjected to CCG on silica gel-60H 
(100–200 mesh). Gradient elution with CHCl3–MeOH 
(1:0, 50:1, 20:1, 10:1 and 0:1), obtained five fractions: A 
(3.7 g), B (4.9 g), C (6.28 g), D (1.5 g) and E (1.8 g).
Fraction D was subjected to CCG on silica gel-60H 
(200–300 mesh), eluted with CHCl3–MeOH (70:30) 
Fig. 1 Chemical structures of components ADHC‑AXpn and DHC‑
Xpn
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and further purified by Sephadex G10 CCG, eluted with 
MeOH to obtain ADHC-AXpn (15 mg).
Fraction C was subjected to repeated CCG on silica 
gel-60H (200–300 mesh), eluted with CHCl3 and acetone 
(3:1) to give sub-fractions 1–5. Sub-fraction 5 was sub-
jected to CCG on silica gel-60H (200–300 mesh), eluted 
in gradient with CHCl3-MeOH (90:10, 85:15 and 80:20). 
The fraction eluted by CHCl3-MeOH (80:20) was puri-
fied by Sephadex G10 CCG, and eluted with MeOH, to 
give DHC-Xpn (40 mg). Chemical structures of ADHC-
AXpn and DHC-Xpn were elucidated by their spectral 
data (IR, MS and 1H, 13C-NMR) and by comparison with 
data in the literature. The purity of isolated components 
was determined over 98  % by peak area normalization 
method in HPLC analysis by an Agilent 1200 liquid 
chromatography system (HP Agilent Technologies, Palo 
Alto, CA, USA).
Cell culture
Cell lines MCF-7 (estrogen receptor-positive phenotype), 
HepG2, HeLa and PC3 cells were obtained from Ameri-
can type culture collection (Manassas, VA, USA). HepG2/
ADM cells (multidrug resistance phenotype) were kindly 
provided by Prof. Kwok-Pui Fung (The Chinese Univer-
sity of Hong Kong, Hong Kong, China). Human MCF10A 
mammary epithelial cells were obtained from Invitrogen 
(Carlsbad, CA, USA). The MCF-7, HepG2, HepG2/ADM 
and PC3 cells were cultured in RPMI-1640 medium sup-
plemented with 10 FBS and 1  % (v/v) P/S at 37 ℃ in a 
humidified incubator containing 5  % CO2. HeLa cells 
were cultured in DMEM medium with the same culture 
condition mentioned above. Human MCF10A mammary 
epithelial cells were cultured in a condition mentioned 
previously [11]. HepG2/ADM cells were cultured with 
1.2  μM of Dox; during cell passage to keep their multi-
drug resistance property as compared with the corre-
sponding parental cells.
Cell viability assay
The inhibitory effects of ADHC-AXpn and DHC-Xpn 
on the growth of tested cells were evaluated by MTT 
assay. Briefly, all tested cells (0.8 × 104/well) were seeded 
in 96-well plates, cultured for 24 h, then exposed to dif-
ferent concentrations of ADHC-AXpn and DHC-Xpn, 
respectively for another 24 or 48 h. Subsequently, 30 μL 
of 5  mg/mL MTT dissolved in PBS was added to each 
well and incubated for 4  h after removing the media. 
Formazan crystals were dissolved with 100 μL of DMSO, 
with absorbance at 490  nm measured by Bio-Rad 680 
microplate reader (Bio-Rad, CA, USA). Cell viability was 
determined as a percentage of the control, with Dox as 
positive control.
Colony formation assay
MCF-7 cells (2.5 × 105/well) were seeded in 6-well plates, 
cultured for 24  h, then exposed to different concentra-
tions of ADHC-AXpn (20, 30 or 35 μM) for 48 h before 
digestion in 0.25 % trypsin to reconstitute single-cell sus-
pensions. Cell suspensions were then transferred into 
6-well plates (600 cells/well) and incubated at 37 ℃ for 
12 days. The formed colonies were fixed in 4 % paraform-
aldehyde for 30  min and stained with 1  % crystal vio-
let for 5  min. These experiments were performed three 
times. Colonies with diameters larger than 0.5 mm were 
counted to calculate the colony formation rate.
Hoechst 33258 staining assay
The nuclear morphology of cells treated with ADHC-
AXpn was observed with a Hoechst 33258 staining assay. 
MCF-7 cells (2.5 × 105/well) were seeded in 6-well plates, 
cultured for 24  h, and treated with different concentra-
tions of ADHC-AXpn (20, 30 or 35  μM) for 48  h. The 
cells were then washed three times with PBS, fixed in 4 % 
paraformaldehyde at 4 ℃ for 30  min, and stained with 
10 μg/mL of Hoechst 33258 for 15 min at 37 ℃. Changes 
in nuclear morphology were monitored with an Olympus 
IX51 inverted microscope (Olympus Corporation of the 
Americas, Inc., Central Valley, PA, USA).
Cell cycle analysis
Cell cycle distribution was analyzed by a fluorescent 
probe propidium iodide (PI) staining assay. MCF-7 cells 
(2.5  ×  105/well) were seeded in 6-well plates, cultured 
for 24  h, then treated with different concentrations of 
ADHC-AXpn (20, 30 or 35 μM) for 24 or 48 h. Cells were 
then collected and fixed with 75 % ethanol at 4 ℃ over-
night. After centrifugation in an Eppendorf 5417R cen-
trifuge (Eppendorf Corp., Hamburg, Germany) at 800g 
for 5 min, the cells were incubated with PBS containing 
0.02  mg/mL PI and 0.1  mg/mL RNase A in darkness at 
37 ℃ for 30  min. The emitting fluorescence was meas-
ured by Guava Easy Cytometer (Guava Technologies, 
Millipore, Billerica, MA, USA); data were analyzed with 
MultiCycle AV software (Phoenix Flow Systems, San 
Diego, CA, USA).
Annexin V‑FITC/PI double staining assay for apoptosis
MCF-7 cells (2.5 × 105/well) were seeded in 6-well plates, 
cultured for 24 h, and exposed to differing concentrations 
of ADHC-AXpn (20, 30 or 35  μM) for 36  h. Cells were 
then collected and stained by Alexa Fluor® 488 Annexin 
V/dead cell apoptosis kit according to manufacturer 
instructions. Green fluorescence emitted from Annexin 
V-FITC and red fluorescence from PI were detected by 
Guava Easy Cytometer (Guava Technologies, Millipore, 
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Billerica, MA, USA). Data were analyzed by FlowJo 7.6 
software (TreeStar, SanCarlos, CA, USA).
Measurement of mitochondrial membrane potential 
(MMP)
Changes in MMP were measured using a lipophilic 
cationic fluorescent probe JC-1. Briefly, MCF-7 cells 
(2.5 × 105/well) were seeded in 6-well plates, cultured for 
24 h, then treated with ADHC-AXpn (20, 30 or 35 μM) 
for 24  h. The cells were collected and incubated with 
5 μM JC-1 in darkness at 37 ℃ for 15 min, then assayed 
with a Guava Easy Cytometer (EasyCyte 8 HT, Millipore, 
USA) to evaluate changes in MMP..
Western blotting assay
MCF-7 cells (2.5  ×  105/well) were seeded in 100-mm 
culture dishes, cultured for 24 h, then incubated with dif-
fering concentrations of ADHC-AXpn for various times. 
Cells were then collected by trypsinization with 0.25  % 
Trypsin-EDTA and transferred to centrifuge tubes. After 
centrifugation at 800g for 5 min, cells were washed twice 
with ice-cold PBS and then lysed in RIPA buffer contain-
ing 0.5 M DTT, 0.1 M PMSF and 20× phosphatase inhib-
itor for 30  min on ice. Protein samples were harvested 
by centrifugation at 12,000g at 4 ℃ for 12  min. Protein 
contents were quantified with BCA Protein Assay Kit 
(Thermo Scientific Pierce, Rockford, USA). The protein 
samples (35  μg) along with a rainbow-colored protein 
molecular marker (Amersham, Buckinghamshire, UK) 
were separated by 10  % SDS-PAGE and transferred to 
polyvinylidene fluoride (PVDF) membranes (Millipore, 
Bedford, MA, USA) by a semi-dry transfer apparatus 
(Bio-Rad, CA, USA). The membranes were blocked with 
5  % nonfat dry milk in Tris-buffered saline containing 
0.1  % Tween-20 (TBS-T) at room temperature for 1  h 
and incubated overnight with primary antibodies con-
taining 5  % BSA at 4 ℃. Membranes were washed with 
TBS-T three times and appropriate secondary antibodies 
conjugated with horseradish peroxidase were added and 
incubated for another hour. Finally, immunoblots were 
visualized by enhanced chemiluminescence detection 
reagents, with β-actin as a loading control.
Statistical analysis
Each experiment was performed for three times and 
data were presented as mean ± standard deviation (SD). 
Analysis of variance (ANOVA) was performed to detect 
significant differences. In multiple comparisons, Tukey 
post-test was used. P value less than 0.05 was consid-
ered statistically significant. Analyses of dose-, concen-
tration- and time-dependent effects were performed 
by sigmoidal non-linear regression. All statistical anal-
ysis tests were performed by Graph Pad Prism 5.0 for 
Windows (GraphPad Software, San Diego California, 
USA).
Results
Structure elucidation of ADHC‑AXpn and DHC‑Xpn
ADHC-AXpn was isolated as a white powder. The 
HR-FAB-MS showed a pseudo-molecular ion peak at 
m/z 725.3887 [M  +  Na]+ (calc. 725.3893), which sup-
ported the molecular formula as being C39H58O11. The 
IR spectrum displayed the presence of hydroxyl groups 
(3338 cm−1) and a carbonyl group (1730 cm−1). The 1H-
NMR spectrum (Table 1) showed signals of cyclopropane 
methylene groups at δ 0.43 and 0.96  ppm (each 1H, d, 
J = 4.0 Hz), six methyl groups at δ 1.05, 1.08, 1.13, 1.20, 
1.65 and 1.67  ppm; an aromatic proton at δ 4.82  ppm 
(d, J = 8.0 Hz), and a series of overlapped signals, which 
suggested that ADHC-AXpn was a cycloartane-type 
triterpene glycoside [12]. The 13C-NMR (Table  1) dis-
played the diagnostic signals of two oxygen-bearing 
alkyl carbons at δ 87.0 (C-24) and 72.1 ppm (C-23), and 
an oxygen-bearing quaternary carbon at δ 113.0  ppm 
(C-16), which implied that ADHC-AXpn was a cimige-
nol-type triterpene [13]. By fully comparing 1H and 13C 
NMR spectral data of ADHC-AXpn with those of the 
known component 25-O-acetyl-7,8-didehydrocimigenol-
3-O-β-d-xylopyranoside (25-AC) [12], the structure of 
ADHC-AXpn was similar to that of 25-AC, excepting 
an additional acetyl moiety. When the 13C-NMR spec-
trum of ADHC-AXpn was compared with that of 25-AC, 
the signals of C-1′ and C-3′ were seen to shift to higher 
field by 2.6 and 2.0 ppm, while the signal of C-2′ shifted 
to lower field. These chemical shift variations suggested 
an acetyl moiety was linked to the C-2′ of the xylose unit 
[12]. Locations of the two acetyl groups were directly 
confirmed by hetero-nuclear multiple bond correlation 
(HMBC) experiments (Fig.  2). Briefly, significant cor-
relation was observed between H-2′ (δH 5.56  ppm, dd, 
J =  7.5, 8.1  Hz) and the carbonyl signal at δ170.3  ppm, 
which indicated an acetyl group was assignable to C-2′. 
The methyl signals at δH 1.65 ppm (Me-26)/δH 1.67 ppm 
(Me-27) also showed correlations with a quaternary car-
bon signal at δC 83.44 ppm (C-25), the methine carbon 
signal at δC 87.05  ppm (C-24), and the methyl carbon 
signals at δC 21.58  ppm (C-27)/δC 24.14  ppm (C-26), 
which indicated that another acetyl group was located at 
C-25. A complete 1H and 13C-NMR spectral assignment 
of ADHC-AXpn was summarized in Tables 1 and 2.
Taken together, the structure of ADHC-AXpn was 
formulated as 25-O-acetyl-7,8-didehydrocimigenol-3-
O-β-d-(2-acetyl) xylopyranoside (Fig.  1). The known 
DHC-Xpn was determined as 7,8-didehydrocimigenol-3-
O-β-d-xylopyranoside by comparison of its spectral data 
with those reported in the literature [14].
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Growth inhibition effects of ADHC‑AXpn and DHC‑Xpn 
on carcinoma cells
The inhibitory effects of ADHC-AXpn and DHC-Xpn on 
the viability of various carcinoma cells were determined 
by MTT assay. ADHC-AXpn was much more potent 
than DHC-Xpn in decreasing the viability of the tested 
cells (MCF-7, HepG2/ADM, HepG2, HELA and PC3 
cells) in both 24 and 48 h treatment periods apart from 
PC3 cells (Table  2). Among these cancer cells treated 
with ADHC-AXpn, MCF-7 cells appeared to be more 
sensitive to ADHC-AXpn than other cancer cells, as indi-
cated by the IC50 values (Fig.  3a). As shown in Fig.  3b, 
the colony formation assay also confirmed that ADHC-
AXpn (20, 30 or 35  μM) could inhibit proliferation of 
MCF-7 cells (P = 0.0078, P < 0.001, P < 0.0001). The IC50 
values of ADHC-AXpn in human MCF10A mammary 
epithelial cells at 48 h were 78.63 ± 3.26 μM, which was 
much higher than for cancer cell line MCF-7. These data 
indicated that ADHC-AXpn was selectively cytotoxic for 
cancer cells.
ADHC‑AXpn induces cell cycle arrest in MCF‑7 cells
We investigated the effect of ADHC-AXpn on the MCF-7 
cell cycle by flow cytometry. Treating MCF-7 cells with 
ADHC-AXpn for 24  h induced a G2/M arrest (Fig.  4a). 
The percentage of cells in subG1 phase increased when 
ADHC-AXpn exposure was extended to 48 h. To explore 
the mechanism of ADHC-AXpn-induced G2/M arrest, 
we investigated its effects on G2/M regulatory proteins. 
Western blotting showed ADHC-AXpn caused a time- 
and dose-dependent decrease in cyclin B1 (Fig.  4b). 
ADHC-AXpn decreased cyclin-dependent kinase 1 
(CDK1), which regulates the cell cycle by forming the 
CDK-cyclin complex, and phospho-CDK1 (Thr161). 
ADHC-AXpn arrests the cell cycle in G2/M phase by 
decreasing expression of cyclin B1, CDK1 and phospho-
CDK1 (Thr161).
Induction of apoptosis by ADHC‑AXpn in MCF‑7 cells
Changes of cellular morphology were examined by fluo-
rescent microscopy analysis (Fig.  5a). After treatment 
with different concentrations of ADHC-AXpn (20, 30 
or 35  μM) for 48  h, cells stained with Hoechst 33258 
showed apoptotic features, such as cytoplasmic shrink-
age and condensation of nuclear chromatin. Consistently, 
PI/Annexin V double staining analysis (Fig.  5b) showed 
that treatment with ADHC-AXpn (30 or 35 μM) for 48 h 
led to significantly increased cell percentages in early 
and late apoptotic phases (P = 0.0094 and P = 0.0042 vs. 
control, respectively). Cleavage of PARP was also seen in 
ADHC-AXpn-treated MCF-7 cells (Fig. 5c).
Activation of mitochondrial apoptotic pathway 
and inhibition of Akt phosphorylation
Changes of MMP were measured by a fluorescent 
dye (JC-1) to further investigate the apoptotic path-
way. MCF-7 cells treated with ADHC-AXpn (20, 30 
or 35  μM) for 24  h showed a gradual decrease in the 
Table 1 1H and  13C-NMR (400  MHz) data of  ADHC-AXpn 
in pyridine-d5
Position δH (J = Hz) δC Position δH (J = Hz) δC
1 1.20 m,  
1.51 m
30.43 20 1.57 m 23.67
2 1.87 m,  
2.26 m
29.67 21 0.89 d (6.5) 19.95
3 3.38 dd (4.0, 
11.9)
88.61 22 0.94 m, 2.26 m 38.07
4 40.37 23 4.60 d (9.3) 72.17
5 1.28 m 42.78 24 4.11 s 87.05
6 1.59 m,  
1.90 m
22.58 25 – 83.44
7 6.10 dd (1.3, 
7.5)
113.01 26 1.65 s 24.14
8 – 148.22 27 1.67 s 21.58
9 – 21.95 28 1.13 s 18.74
10 – 28.60 29 1.20 s 25.79
11 1.13 m,  
2.04 m
25.71 30 1.05 s 14.35
12 1.53 m,  
1.62 m
34.31 1′ 4.84 d (7.5) 104.81
13 – 41.49 2′ 5.56 dd (7.5, 
8.1)
75.91
14 – 50.74 3′ 4.13 dd (8.1, 
8.1)
76.51
15 4.27 s 78.44 4′ 4.21 m 71.60





17 1.49 d (10.0) 59.51
18 1.08 s 21.78 25‑COCH3 1.95 s 170.4, 21.5
19 0.43 d  
(4.0),0.96 d 
(4.0)
28.35 2′‑COCH3 2.14 s 170.3, 21.5
Fig. 2 Key HMBC for ADHC‑AXpn
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Table 2 The inhibitory effects of ADHC-AXpn and DHC-Xpn on the viability of human carcinoma cells
ADHC‑AXpn (IC50, μM) DHC‑Xpn (IC50, μM) Dox
24 h 48 h 24 h 48 h 48 h
MCF‑7 30.32 ± 0.79 27.81 ± 1.29 >50 42.14 ± 4.63 4.07 ± 1.33
HepG2 40.73 ± 1.46 35.65 ± 1.17 >50 42.51 ± 2.57 3.80 ± 0.95
HepG2/ADM 33.66 ± 3.64 29.61 ± 0.26 >50 >50 143.47 ± 4.76
HeLa 41.25 ± 0.23 35.73 ± 2.15 >50 >50 4.62 ± 1.37
PC3 >50 >50 >50 >50 5.52 ± 1.19
Fig. 3 Growth inhibitory activity of ADHC‑AXpn in MCF‑7 cells. a Cells were treated with increasing concentrations of ADHC‑AXpn (10 to 50 μM) 
for 24 and 48 h; cell survival was then assessed by MTT assay. Doxorubicin (Dox) exposure at 5 μM was used as a positive control. b After exposure 
to ADHC‑AXpn at concentrations of 20, 30 or 35 μM, cells were seeded onto 6‑well plates (600 cells/well) for assessing colony formation. Data are 
expressed as mean ± SD of three independent experiments with **P = 0.0078; ***P < 0.001
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percentage of cells with high MMP from 94.1 (control) 
to 68.7  %, 63.0 and 55.9  %, respectively (Fig.  6a). We 
examined expression levels of pro-apoptotic protein Bax 
and anti-apoptotic protein Bcl-2. Western blot analy-
sis showed that ADHC-AXpn treatment down-regu-
lated Bcl-2 and clearly up-regulated Bax (Fig.  6b). The 
precursor form of caspase-9 was decreased, whereas 
expression of cleaved caspase-9 was increased. ADHC-
AXpn exposure remarkably decreased p-Akt (Thr308 and 
Ser473), although total Akt showed no visible change.
Raf/MEK/ERK pathway inhibition by ADHC‑AXpn in MCF‑7 
cells
The Raf/MEK/ERK pathway is beneficial for survival 
of MCF-7 cells, and blockage of this pathway can trig-
ger apoptosis [15]. To investigate whether the Raf/MEK/
ERK pathway affects ADHC-AXpn-induced apoptosis, 
we assessed expression levels of p-ERK1/2 and p-c-Raf. 
Compared with the control group, ADHC-AXpn treat-
ment decreased phosphorylation of ERK1/2 in both time- 
and dose-dependent manners (Fig.  6c). The upstream 
Fig. 4 Cell‑cycle arrest induced by ADHC‑AXpn in MCF‑7 cells. a Cell cycle profiles of MCF‑7 cells after treatment with ADHC‑AXpn for 24 or 48 h. 
Cells exposed to indicated concentrations of ADHC‑AXpn were collected, fixed with 75 % ethanol overnight, and stained with PI for 30 min; cell‑
cycle profiles were then determined by flow cytometry. Doxorubicin (dox) exposure at 5 μM was used as a positive control. b Changes in cell‑cycle 
regulator protein expression after exposure to ADHC‑AXpn in MCF‑7 cells. After treatment with ADHC‑AXpn, total cell lysates were immunoblotted 
to detect CDK1, p‑CDK1 (Thr161) and cyclin B1 expression levels, using specific antibodies. β‑actin served as a loading control
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regulator of ERK1/2, p-c-Raf, was also down-regulated 
after exposure to ADHC-AXpn.
Discussion
In the present study, a novel cycloartane triterpenoid, 
ADHC-AXpn and the known DHC-Xpn were isolated 
and identified from C. foetia. The cytotoxic effects of 
these two isolated components on human cancer cells 
MCF-7, HepG2, HepG2/ADM, HeLa, PC3 and nor-
mal human mammary epithelial cells MCF10A were 
assessed by MTT assay and colony formation assay. 
ADHC-AXpn, which possesses acetyl groups at C-25 
and C-2′ in its sugar groups, was more cytotoxic toward 
all tested cell lines than was DHC-Xpn, which bears 
hydroxyl groups at C-25 and C-2′ in its sugar group. 
Addition of a hydrophobic group (such as acetyl or 
halogen) linked to C-25 or other positions remarkably 
increased cytotoxic activity, which were consistent with 
a previous report on the structure–activity relationship 
of cycloartane triterpenoids in other cells [4]. The IC50 
value of ADHC-AXpn for normal human mammary 
epithelial cells MCF10A was higher than those for can-
cer cells.
Activation of the apoptotic pathway in tumor cells 
is a major protective mechanism against the devel-
opment and progression of cancer [16]. On the basis 
Fig. 5 Apoptosis induced by ADHC‑AXpn in MCF‑7 cells. a Representative image of MCF‑7 cells stained with Hoechst 33258 after treatment with 
ADHC‑AXpn for 48 h, under fluorescence microscope; red arrows: cell shrinkage, nuclear fragmentation. b Apoptosis quantification, using Annexin 
V/PI double staining assay after treatment with ADHC‑AXpn for 36 h. MCF‑7 cells were harvested and stained with PI and Annexin V‑FITC in darkness 
for 15 min, followed by flow cytometry analysis. Lower right: Annexin V+/PI− (early apoptosis); upper right: Annexin V+/PI+ (late apoptosis). c Western 
blot showing PARP cleavage in MCF‑7 cell lysates after treatment with ADHC‑AXpn, using indicated antibodies. Loading control: β‑actin; positive 
control: doxorubicin (Dox), 5 μM
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of the detected cytotoxic effects of ADHC-AXpn 
and DHC-Xpn on MCF-7, HepG2, HepG2/ADM, 
HeLa and PC3 cells (Table  2), further studies were 
performed to explore the mechanism of ADHC-
AXpn-induced cell death in MCF-7 cells. To our 
knowledge, our study was the first one to demonstrate 
Fig. 6 Effect of ADHC‑AXpn on mitochondrial function and Raf/MEK/ERK signaling pathway in MCF‑7 cells. a Flow cytometry shows mitochondrial 
membrane depolarization induced by treatment with indicated concentrations of ADHC‑AXpn for 24 h; detached cells were stained with JC‑1; 
generic mitochondrial membrane depolarizer CCCP (20 μM), used as positive control, showed an expected decrease in red fluorescence. b Western 
blot shows caspase activation and changes in expression levels of Bcl‑2 family proteins and Akt proteins in MCF‑7 cells after treatment with ADHC‑
AXpn, using specific antibodies against caspase‑9, cleaved caspase‑9, Bcl‑2 and Bax, Akt and p‑Akt (Thr308 and Ser473), respectively. c Western blot 
shows inhibition of Raf/MEK/ERK signaling pathway related proteins in MCF‑7 cells after treatment with ADHC‑AXpn, using the indicated antibodies; 
loading control: β‑actin
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that ADHC-AXpn could induce MCF-7 cell death via 
apoptosis, accompanied with stereotypical apoptotic 
features that include cell shrinkage, phosphatidylser-
ine (PS) externalization and PARP cleavage. ADHC-
AXpn inhibited cyclin B1 and CDK1, and thereby led 
to clear G2/M arrest.
Apoptosis has two major pathways: the cell death 
receptor-mediated apoptotic pathway and the mito-
chondrial-mediated apoptotic pathway [17]. The lat-
ter is also referred to as the intrinsic apoptosis pathway, 
and it is involved in the caspase-dependent apoptotic 
pathway [18, 19]. Bcl-2 family proteins are major regu-
lators of the mitochondrial pathway; Bcl-2 is a major 
anti-apoptosis protein, integrated in the mitochon-
drial membrane, and Bax is inactive in the cytosol or 
loosely attached to intracellular membranes as a mono-
mer [20, 21]. The over-expression of Bax and lower-
expression of Bcl-2 induce the MMP collapse and a 
subsequent cascade activation of caspases through 
homologous dimerization, and eventually lead to apop-
tosis. Four isolated cycloartane triterpenoids from 





expression of p53 and Bax, resulting in mitochondria-
mediated apoptosis [6]. Our results showed similar phe-
nomena, including changes in Bcl-2 and Bax levels, and 
decreased MMP and caspase-9 activation (Fig.  6a, b), 
implying that mitochondrial dysfunction was involved in 
ADHC-AXpn-induced apoptosis in MCF-7 cells. In addi-
tion, decreased Akt phosphorylation might be involved 
in ADHC-AXpn-induced apoptosis, as Akt activation 
protects cells from apoptosis via inhibiting pro-apoptotic 
molecues [22].
The Raf/MEK/ERK pathway can transduce signals that 
originate from growth factor receptors to transcription 
factors, thus controlling cell survival and proliferation 
[15]. Raf, mediated cell cycle progression by regulating 
cell-cycle associated proteins such as Cdks, cyclins and 
p21Cip1 [23, 24]. The Raf/MEK/ERK pathway also affects 
apoptosis progression. Raf can induce transcription of 
anti-apoptotic genes such as Bcl-2, and activation of the 
Raf/MEK/ERK pathway, leading to phosphorylation and 
inactivation of the pro-apoptotic protein Bad [25–27]. 
ERK1/2 is required for survival signaling and ERK1/2 
inhibition is a crucial part of the apoptotic mechanisms 
of various stimuli [28]. Our present studies on the regu-
latory effects of ADHC-AXpn on cyclin B1, CDK1, cas-
pase-9, Bax and Bcl-2, suggested that the Raf/MEK/ERK 
pathway might be involved in ADHC-AXpn-induced 
apoptosis.
Conclusions
ADHC-AXpn significantly suppressed the growth of 
MCF-7 cells, induced mitochondrial apoptosis and cell-
cycle arrest, and inhibited Raf/MEK/ERK signaling path-
way and Akt phosphorylation.
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